Which finding indicates a therapeutic outcome for a client receiving baclofen?

The indication of a therapeutic outcome for a client receiving baclofen is a decrease in flexor and extensor spasticity. Baclofen is a muscle relaxant that specifically targets spasticity, which is often associated with conditions like multiple sclerosis or spinal cord injury. The primary purpose of baclofen is to alleviate increased muscle tone and spasms, thereby improving mobility and comfort for the patient.

When administering baclofen, healthcare providers look for effective reductions in muscle stiffness and spasms, as this directly correlates with the drug's mechanism of action. A successful therapeutic outcome would manifest as improved ease of movement and decreased discomfort due to spasticity.

Other options do not directly represent the therapeutic effects of baclofen. While an increase in seizure threshold may be beneficial for clients with seizure disorders, it is not a primary target of treatment with baclofen. Similarly, improvement in cognitive function and a decrease in paralysis of extremities do not align with the specific therapeutic effects intended with baclofen use in managing spasticity. Therefore, the stated therapeutic outcome of decreased flexor and extensor spasticity is the most accurate reflection of the drug's intended effects.